Diagnosis and Management of Porphyria Cutanea Tarda

Diagnostic Approach

The diagnosis of Porphyria Cutanea Tarda (PCT) requires biochemical testing showing elevated urinary porphyrins, particularly uro- and heptacarboxyl porphyrins, followed by appropriate management targeting underlying risk factors and reducing porphyrin levels through phlebotomy or low-dose antimalarials, as recommended by the American Association for the Study of Liver Diseases 1, 2
Plasma fluorescence scanning is recommended as a first-line analysis for patients with cutaneous symptoms suggestive of PCT, according to the European Association for the Study of the Liver 2
Fractionation of porphyrins in urine is the standard approach for investigating a potential PCT diagnosis, as suggested by the American Association for the Study of Liver Diseases 2
Samples should be protected from light to avoid falsely low results, as recommended by the American Association for the Study of Liver Diseases 1
PCT is characterized by elevated uro- and heptacarboxyl porphyrins in urine, as reported by the European Association for the Study of the Liver 2
Hepta-, penta-, and isocoproporphyrins predominate in feces, according to the European Association for the Study of the Liver 2

Fractionation of porphyrins in plasma may facilitate diagnosis in patients with kidney failure, as suggested by the European Association for the Study of the Liver 2
Genetic testing for UROD gene mutations should be considered to differentiate between sporadic (type I) and familial (type II) PCT, as recommended by the American Gastroenterological Association 3
Relying solely on clinical presentation without biochemical confirmation should be avoided, as warned by the American Association for the Study of Liver Diseases 1
Using only total urine porphyrin tests without fractionation should be avoided, as cautioned by the European Association for the Study of the Liver 2
Failing to protect samples from light exposure, leading to falsely low results, should be avoided, as advised by the American Association for the Study of Liver Diseases 1

The American Autoimmunity Association notes that patient history should specifically assess for known PCT risk factors, including alcohol consumption, hepatitis C virus infection, and iron overload or hereditary hemochromatosis, which are associated with an increased risk of developing PCT 4
The presence of risk factors such as alcohol consumption, hepatitis C virus infection, and iron overload or hereditary hemochromatosis can contribute to the development of PCT, as reported by the Autoimmunity Reviews 4

Measurement of uroporphyrinogen decarboxylase (UROD) activity in erythrocytes can help differentiate between sporadic (type I) and familial (type II) PCT, according to the Autoimmunity Reviews 4
The Autoimmunity Association recommends considering pseudoporphyria, which can mimic PCT clinically but lacks the characteristic biochemical findings, in the differential diagnosis of PCT 4